The Evolution of Testing: Trends Shaping 2026

The Galleri Trial: A $2B Blood Test That Failed Its Primary Endpoint

Grail's Galleri multi-cancer early detection test, once hailed as the holy grail of oncology, failed its primary endpoint in a randomized controlled trial involving 142,942 asymptomatic NHS patients. The goal was to reduce late-stage cancer diagnoses by adding the blood test to standard screening over three years.

The data, presented at ASCO 2024, showed no statistically significant reduction in stage III/IV cancers. Despite detecting over 50 cancer types, the test did not shift diagnoses to earlier stages when combined with routine screening.

“While the Galleri-NHS study results show some encouraging trends toward tumour downstaging, it is important to recognise that the trial did not statistically reduce late-stage cancers by its predefined primary endpoint.” — Dr. Julie Gralow, ASCO Chief Medical Officer

• 142,942 asymptomatic patients enrolled, each providing annual blood samples for three years while continuing standard screening.
• Half received the Galleri test; the other half served as controls with standard care only.
• The trial cost an estimated $2 billion to conduct, including development and analysis.

The failure underscores a fundamental truth: detecting cancer early via blood markers does not automatically translate into improved outcomes if the test cannot catch tumors at a treatable stage or if patients do not adhere to follow-up protocols.

Three Pitfalls in Testing Validation That Cross Industry Boundaries

The Galleri trial's collapse offers three specific lessons for any domain relying on AI-driven diagnostics or automation—including software testing. These pitfalls are not unique to healthcare.

First, surrogate endpoints must be rigorously linked to outcomes. Galleri's high detection rate for multiple cancers did not correlate with stage shift at diagnosis. In software, coverage metrics like code coverage or test pass rates are often used as proxies for quality, but they can mask real defects.

Second, control group design matters. The NHS-Galleri trial was a randomized controlled trial—half got the test, half did not. Observational studies might have shown false promise. Similarly, A/B testing of testing strategies (e.g., with and without a new AI tool) is rare but essential in DevOps.

Third, overreliance on pattern recognition without mechanistic understanding is dangerous. Galleri's AI flagged signals but could not explain why or when cancers would progress. Black-box models in test generation or failure prediction risk the same false confidence. As regulation tightens, AI validation standards will demand interpretability across industries.

“The trial flopped,” one senior cancer figure told the Guardian.

Software teams must learn that even large-scale AI deployments can fail if the underlying causal chain is broken. The lesson applies equally to automated test case generation and CI/CD predictive analytics.

How Software Testing Can Avoid a Similar 'Black Box' Crisis

Three actions can prevent software testing from repeating Galleri's mistake. First, autonomous test generation tools need causal validation—not just coverage metrics but proof they find real bugs that matter to users.

Second, predictive analytics in CI/CD pipelines should be evaluated on business outcomes, not speed. For example, reducing production incidents by a measurable percentage is a better success criterion than reducing test execution time by hours.

Third, interpretable AI is non-negotiable. Engineers must understand why a test was generated or a failure predicted. This aligns with emerging regulatory frameworks. AI adoption in law has already triggered demands for explainability—testing should follow suit.

The Galleri failure also highlights the pitfall of the 'simple blood test' narrative. In software, a shiny new AI testing tool promising 90% defect detection can hide fundamental flaws in data quality or test design. Teams should demand rigorous, randomized validation before trusting such tools in production.

Clinical-style randomized trials are rare in software testing but could validate AI tools. A/B testing of test strategies is a pragmatic alternative.

The 142,942-patient size of the Galleri trial proves that big data alone does not guarantee meaningful improvement. Sound experimental design, causal reasoning, and outcome-driven metrics are the only path to trustworthy AI in testing.

Key Takeaways

• Large-scale AI-in-testing initiatives must define primary success metrics tied to user-facing quality, not proxy measures.
• Beware of the 'simple blood test' narrative: advanced automation can mask fundamental flaws in test design or data quality.
• Clinical-style randomized trials are rare in software testing but could validate AI tools; A/B testing of test strategies is a pragmatic alternative.
• The Galleri trial's 142,942-patient size demonstrates that even massive datasets do not guarantee meaningful improvement without sound experimental design.
• Interpretability and causal reasoning are critical for AI in testing—black-box models risk repeating the Galleri outcome in a different domain.